Search hospitals > North Carolina > Concord
Atrium Health Cabarrus/LCI-Concord
Claim this profileConcord, North Carolina 28025
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Cervical Adenocarcinoma
Conducts research for Relapse
Conducts research for Lung Cancer
87 reported clinical trials
13 medical researchers
Summary
Atrium Health Cabarrus/LCI-Concord is a medical facility located in Concord, North Carolina. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Cervical Adenocarcinoma, Relapse, Lung Cancer and other specialties. Atrium Health Cabarrus/LCI-Concord is involved with conducting 87 clinical trials across 174 conditions. There are 13 research doctors associated with this hospital, such as Nilanjan Ghosh, Earle Burgess, MD, John H. Heinzerling, and Daniel R. Carrizosa.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Top PIs
Nilanjan GhoshLevine Cancer Institute7 years of reported clinical research
Studies Lymphoma
Studies Mediastinal Lymphoma
9 reported clinical trials
13 drugs studied
Earle Burgess, MDCarolinas Medical Center/Levine Cancer Institute3 years of reported clinical research
Studies Breast Cancer
Studies Prostate Cancer
6 reported clinical trials
26 drugs studied
John H. HeinzerlingCarolinas Medical Center/Levine Cancer Institute9 years of reported clinical research
Studies Lung Cancer
Studies Small Cell Lung Cancer
6 reported clinical trials
21 drugs studied
Daniel R. CarrizosaCarolinas Medical Center/Levine Cancer Institute6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
6 reported clinical trials
14 drugs studied
Clinical Trials running at Atrium Health Cabarrus/LCI-Concord
Small Cell Lung Cancer
Parotid Gland Cancer
Lung Cancer
Prostate Cancer
Breast Cancer
Squamous Cell Carcinoma
Skin Cancer
Oropharyngeal Carcinoma
Kidney Cancer
Cancer
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
Single vs Multiple Dose Radiation
for Brain Metastases
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.
Recruiting1 award N/A
Radiation Therapy + Atezolizumab
for Small Cell Lung Cancer
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Recruiting1 award Phase 2 & 311 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Atrium Health Cabarrus/LCI-Concord?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.